new developments in sarcopenia: findings from the second ... · conceptual advances in sarcopenia...
TRANSCRIPT
New developments in sarcopenia: findings from the second
European Working Group on Sarcopenia in Older People
Alfonso J. Cruz-JentoftHospital Universitario Ramón y Cajal (IRYCIS)
Madrid. Spain
BGS Autumn 2
018
There is no universally agreed definition of sarcopenia
Source: Google Scholar, accessed November 6th, 2018
• EWGSOP (2010): 5287 citations
• IWGS (2011): 1488 citations
• AWGS (2014): 935 citations
• FNIH (2014): 535 citations
BGS Autumn 2
018
2010April 2010
April 2010
May 2011
July 2011
Musclemass
AND
Musclefunction
BGS Autumn 2
018
Do we need an update of the 2010 definition of sarcopenia?
BGS Autumn 2
018
Conceptual advances in sarcopenia
Musclemass +
functionSyndromic approach
Adverse outcomes
Degreesof severity
BGS Autumn 2
018
Problems to be addressed• Sarcopenia begins earlier in life (important for interventions and
prevention).
• Conceptualization of sarcopenia as a muscle disease.
• Problems in accurately measuring and categorizing muscle massand muscle quality.
• Outcome measures for interventions not agreed.
• SARCOPENIA HAS NOT REACHED MAINSTREAM CLINICAL PRACTICE (is it still too complicated)? BGS Autu
mn 201
8
Parameters Variables Measurementinstrument Cutoff-points
Muscle massMuscle strengthPhysical performance?Mass: total? regional? appendicular? single muscle?
Muscle strength: where? single or groups?… Muscle mass: anthropometry? BIA? DXA? CT? MRI?
Biochemistry? Protocols, equations, assumptions… Cutoff points for each variable and instrument:
reference populations? local or global?…
OUTCOME VARIABLESPerformance, mobility, ADL, falls, NH admission, PRO…BGS Autu
mn 201
8
2018 EWGSOP}Alfonso J. CRUZ-JENTOFT, Spain}Gülistan BAHAT, Turkey}Jürgen BAUER, Germany}Yves BOIRIE, France}Olivier BRUYÉRE, Belgium}Tommy CEDERHOLM, Sweden}Cyrus COOPER, UK}Francesco LANDI, Italy}Yves ROLAND, France}Avan SAYER, UK
}Stephane SCHNEIDER, France}Cornel SIEBER, Germany}Eva TOPINKOVÁ, Czech Republic}Maurits VANDEWOUDE, Belgium}Marjolein VISSER, Netherlands}Mauro ZAMBONI, Italy
}Cecilia HOFFMAN, Medical Writer
}Ricardo RUEDA + Carole GLENCORSE, Abbott Nutrition International (Observers)
WRITING GROUP
BGS Autumn 2
018
}Ivan BAUTMANS, Belgium}Jean Pierre BAEYENS, Belgium}Matteo CESARI, Italy}Antonio CHERUBINI, Italy}John KANIS, UK}Marcello MAGGIO, Italy}Finbarr MARTIN, UK
}Jean-Pierre MICHEL, Switzerland}Kaisu PITKALA, Finland}Jean-Yves REGINSTER, Belgium}René RIZZOLI, Switzerland}Mª Dolores SÁNCHEZ, Spain}Jos SCHOLS, Netherlands
EXTENDED GROUP2018 EWGSOP
BGS Autumn 2
018
Age and Ageing 2018; 0: 1–16doi: 10.1093/ageing/afy169
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Geriatrics Society.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-
use, distribution, and reproduction in any medium, provided the original work is properly cited. Forcommercial re-use, please contact [email protected]
GUIDELINES
Sarcopenia: revised European consensuson definition and diagnosisALFONSO J. CRUZ-JENTOFT
1, GÜLISTAN BAHAT2, JÜRGEN BAUER3, YVES BOIRIE4, OLIVIER BRUYÈRE5,
TOMMY CEDERHOLM6, CYRUS COOPER
7, FRANCESCO LANDI8, YVES ROLLAND
9, AVAN AIHIE SAYER10,STÉPHANE M. SCHNEIDER
11, CORNEL C. SIEBER12, EVA TOPINKOVA13, MAURITS VANDEWOUDE
14,MARJOLEIN VISSER
15, MAURO ZAMBONI16, WRITING GROUP FOR THE EUROPEAN WORKING GROUP ON
SARCOPENIA IN OLDER PEOPLE 2 (EWGSOP2), AND THE EXTENDED GROUP FOR EWGSOP21Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain2Department of Internal Medicine, Division of Geriatrics, Istanbul Medical School, Istanbul University, Istanbul, Turkey3Center for Geriatric Medicine, University Heidelberg, Agaplesion Bethanien Krankenhaus, Heidelberg, Germany4Research Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France5Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium6Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, and ThemeAgeing, Karolinska University Hospital, Stockholm, Sweden7MRC Lifecourse Epidemiology Unit, University of Southampton; Southampton, UK; and Department of Epidemiology,University of Oxford, OX, UK8Instituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore, Roma, Italy9Department of Geriatrics, Hospital and University of Toulouse, Toulouse, France10NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Faculty of MedicalSciences, Newcastle University, Newcastle, UK11Department of Gastroenterology and Clinical Nutrition, Centre Hospitalier Universitaire de Nice, Université Côte d’Azur,Nice, France12Department of Internal Medicine-Geriatrics, Institute for Biomedicine and Ageing, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany13Department of Geriatrics, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic14Department Geriatrics, University of Antwerp, Ziekenhuisnetwerk Antwerpen (ZNA), Antwerp, Belgium15Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam; and the Amsterdam Public Health ResearchInstitute; Amsterdam, The Netherlands16Department of Medicine, Geriatric section, University of Verona, Verona, Italy
Address correspondence to: Alfonso J. Cruz-Jentoft, MD, Servicio de Geriatría, Hospital Universitario Ramón y Cajal, Ctra.Colmenar, km 9.1, 28034 Madrid, Spain. Tel: +34 913368172; Fax: +34 913368172. Email: [email protected]
Abstract
Background: in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopeniadefinition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the WorkingGroup met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that hasbuilt over the last decade. This paper presents our updated findings.Objectives: to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia.Recommendations: sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across alifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paperon sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of lowmuscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative ofsevere sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and
1
Dow
nloaded from https://academ
ic.oup.com/ageing/advance-article-abstract/doi/10.1093/ageing/afy169/5126243 by guest on 14 O
ctober 2018
BGS Autumn 2
018
Definition of sarcopenia
Sarcopenia is a progressive and generalized skeletal muscle disorderthat is associated with increased likelihood of adverse outcomesincluding falls, fractures, physical disability, and mortality.
Muscle failure
BGS Autumn 2
018
Operational definition of sarcopenia:EWGSOP
LOW MUSCLE
MASS
LOW PHYSICAL PERFORMANCE
LOW MUSCLE STRENGH
AND/OR SARCOPENIA
BGS Autumn 2
018
New operational definition of sarcopenia:EWGSOP2
LOW MUSCLE QUANTITY/
QUALITY
LOW PHYSICAL PERFORMANCE
LOW MUSCLE STRENGH
PROBABLE SARCOPENIA
SEVERE SARCOPENIA
DEFINITE SARCOPENIA
weak, slow walking speed, difficulty rising from a chair orweight loss/muscle wasting). In such cases, further testingfor sarcopenia is recommended [2].
EWGSOP2 recommends use of the SARC-F question-naire as a way to elicit self-reports from patients on signsthat are characteristic of sarcopenia. SARC-F can be readilyused in community healthcare and other clinical settings.The SARC-F is a 5-item questionnaire that is self-reportedby patients as a screen for sarcopenia risk [12]. Responsesare based on the patient’s perception of his or her limita-tions in strength, walking ability, rising from a chair, stairclimbing and experiences with falls. This screening tool wasevaluated in three large populations—the African AmericanHealth Study, Baltimore Longitudinal Study of Aging andthe National Health and Nutrition Examination study [12],
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Choosing tools for sarcopenia case finding and for measurement of muscle strength, muscle mass and physical per-formance in clinical practice and in research
Variable Clinical practice Research studies Video for practical instruction, reference
Case finding SARC-F questionnaireIshii screening tool
SARC-F Malmstrom et al. (2016) [12]Ishii et al. (2014) [40]
Skeletal musclestrength
Grip strength Grip strength Roberts et al. (2011) [41]Chair stand test (chair rise test) Chair stand test (5-times sit-to-stand) American Academy of Orthotists &
Prosthetistshttps://www.youtube.com/watch?v=_jPl-IuRJ5A
Skeletal musclemass orSkeletalmuscle quality
Appendicular skeletal muscle mass(ASMM) by Dual-energy X-rayabsorptiometry (DXA)*
ASMM by DXA Schweitzer (2015) [42]Mitsiopoulos (1998) [43]
Whole-body skeletal muscle mass (SMM)or ASMM predicted by Bioelectricalimpedance analysis (BIA)*
Whole-body SMM or ASMM by MagneticResonance Imaging (MRI, total body protocoI)
Shen (2004) [44]Sergi (2017) [45]Maden-Wilkinson (2013) [46]Heymsfield (1990) [47]Kim (2002) [48]Yamada (2017) [49]
Mid-thigh muscle cross-sectional area by ComputedTomography (CT) or MRI
Lee (2004) [50]
Lumbar muscle cross-sectional area by CTor MRI
Lumbar muscle cross-sectional area by CT or MRI Van der Werf (2018) [51]Derstine (2018) [52]
Muscle quality by mid-thigh or total body musclequality by muscle biopsy, CT, MRI or Magneticresonance Spectroscopy (MRS)
Goodpaster (2000) [53]Reinders (2016) [54]Grimm (2018) [55]Distefano (2018) [56]Ruan (2007) [57]
Physicalperformance
Gait speed Gait speed NIH Toolbox 4 Meter Walk Gait SpeedTest
https://www.nia.nih.gov/research/labs/leps/short-physical-performance-battery-sppb
https://www.youtube.com/watch?v=xLScK_NXUN0
Short physical performance battery (SPPB) SPPB Short Physical Performance BatteryProtocol
https://research.ndorms.ox.ac.uk/prove/documents/assessors/outcomeMeasures/SPPB_Protocol.pdf
NIH Toolboxhttps://www.nia.nih.gov/research/labs/leps/short-physical-performance-battery-sppb
Timed-up-and-go test (TUG) TUG Mathias (1986) [40]400-meter walk or long-distance corridorwalk (400-m walk)
400-m walk Newman (2006) [41]
*Sometimes divided by height2 or BMI to adjust for body size.
Table 1. 2018 operational definition of sarcopenia
Probable sarcopenia is identified by Criterion 1.Diagnosis is confirmed by additional documentation of Criterion 2.If Criteria 1, 2 and 3 are all met, sarcopenia is considered severe.
• Low muscle strength• Low muscle quantity or quality• Low physical performance
A. J. Cruz-Jentoft et al.
4
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
BGS Autumn 2
018
Case finding
• In clinical practice, case-finding may start when a patient reportssymptoms or signs of sarcopenia (i.e., falling, feeling weak, slowwalking speed, difficulty rising from a chair, or weight loss/musclewasting). In such cases, further testing for sarcopenia isrecommended.
• EWGSOP2 recommends use of the SARC-F questionnaire as a wayto elicit self-reports.
BGS Autumn 2
018
Measuring sarcopenia parameters
MUS
CLE
STRE
NGTH • Handgrip
strength• Chair
stand test
MUS
CLE
QUAN
TITY • DXA
• (BIA)• CT / MRI
PHYS
ICAL
PER
FORM
ANCE • Gait
speed• SPPB• TUG• 400 m
walk
BGS Autumn 2
018
Alternative and new tools
• Lumbar 3rd vertebra imaging by computed tomography• Mid-thigh muscle measurement• Psoas muscle measurement with computed tomography• Muscle quality measurements?• Creatine dilution test• Ultrasound assessment of muscle• Specific biomarkers or panels of biomarkers• SarQoL questionnaireBGS Autu
mn 201
8
Cut-off points!Test Cut-off points for
menCut-off points for women
References
EWGSOP2 sarcopenia cutoff points for low strength by chair stand and grip strengthGrip strength <27 kg <16 kg Dodds, 2014[26]
Chair stand >15 sec for 5 rises Cesari, 2009[67]
EWGSOP sarcopenia cut-off points for low muscle quantityASM < 20 kg < 15 kg Studenski,
2014[3]ASM/height2 < 7.0 kg/m2 < 6.0 kg/m2 Gould,
2014[125]
BGS Autumn 2
018
Cut-off points!Test Cut-off points
for menCut-off points for women
References
EWGSOP sarcopenia cut-off points for low performanceGait speed ≤ 0.8 m/sec Cruz-Jentoft,
2010[1]
Studenski, 2011[84]
SPPB ≤ 8 point score Pavasini, 2016[90]
Guralnik, 1995[126]
TUG ≥ 20 sec Bischoff, 2003[127]
400m walk test Non-completion or ≥ 6 min for completion
Newman, 2006[128]BGS Autu
mn 201
8
New algorithm
Sarcopenic obesity is a distinct condition, and there areongoing initiatives to improve its definition. Sarcopenic obes-ity is therefore outside of the scope of this article.
Frailty
Frailty is a multidimensional geriatric syndrome that is char-acterized by cumulative decline in multiple body systems or
functions [139, 140], with pathogenesis involving physical aswell as social dimensions [141]. Frailty increases vulnerabilityto poor health outcomes such as disability, hospital admis-sion, reduced quality of life and even death [141, 142].
The physical phenotype of frailty, described by Fried andco-workers [143], shows significant overlap with sarcopenia;low grip strength and slow gait speed are characteristic ofboth. Weight loss, another diagnostic criterion for frailty, isalso a major etiologic factor for sarcopenia. Treatmentoptions for physical frailty and for sarcopenia likewise over-lap—provision of optimal protein intake, supplementation ofvitamin D, and physical exercise [19, 144, 145].
Taken together, frailty and sarcopenia are still distinct—one a geriatric syndrome and the other a disease. While sar-copenia is a contributor to the development of physicalfrailty, the syndrome of frailty represents a much broaderconcept. Frailty is seen as the decline over a lifetime in mul-tiple physiological systems, resulting in negative conse-quences to physical, cognitive, and social dimensions.Frailty’s diagnostic tools reflect these multiple dimensions,e.g. the Groningen Frailty Indicator, the Frailty Index ofRockwood et al. and others [146–149].
Malnutrition-associated sarcopenia
The sarcopenia phenotype is also associated with malnutri-tion, regardless of whether the malnourished condition isrooted in low dietary intake (starvation, inability to eat),reduced nutrient bioavailability (e.g. with diarrhea, vomiting)or high nutrient requirements (e.g. with inflammatory dis-eases such as cancer or organ failure with cachexia) [150,151]. Low muscle mass has recently been proposed as partof the definition of malnutrition [152]. Also in malnutrition,low fat mass is usually present, which is not necessarily thecase in sarcopenia [151, 152].
Looking ahead: gaps in sarcopenia research
There are still many gaps in our knowledge about sarcope-nia—its initiation and progression, diagnostic tools and cut-off points, and outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. EWGSOP sarcopenia cut-off points
Test Cut-off points for men Cut-off points for women References
EWGSOP2 sarcopenia cut-off points for low strength by chair stand and grip strengthGrip strength <27 kg <16 kg Dodds (2014) [26]Chair stand >15 s for five rises Cesari (2009) [67]
EWGSOP sarcopenia cut-off points for low muscle quantityASM <20 kg <15 kg Studenski (2014) [3]ASM/height2 <7.0 kg/m2 <6.0 kg/m2 Gould (2014) [125]
EWGSOP sarcopenia cut-off points for low performanceGait speed ≤0.8 m/s Cruz-Jentoft (2010) [1]
Studenski (2011) [84]SPPB ≤8 point score Pavasini (2016) [90]
Guralnik (1995) [126]TUG ≥20 s Bischoff (2003) [127]400 m walk test Non-completion or ≥6min for completion Newman (2006) [128]
LOW
LOW
POSITIVEOR PRESENT
Sarcopenia suspected
MuscleassessmentMass, Quality
PHYSICAL PERFORMANCE
SPPB, TUG, 400m
Sarcopenia confirmed
LOW Sarcopenia severe
DETERMINE SEVERITY
CONFIRM
FIND CASES
ASSESSMusclestrength
Grip strength, chairstands
NORMAL
rescreenlater
SARC-Forclinical
suspicion
No sarcopenia;rescreen later
Sarcopenia probable*
NEGATIVE
Muscle quantityor quality
DXA; BIA, CT, MRI
PhysicalPerformance
Gait speed, SPPB, TUG, 400m walk
Sarcopenia confirmed
Sarcopenia severeSEVERITY
Muscle strengthGrip strength,
Chair stand test
No sarcopenia; rescreen later
In clinical practice, this is enough to
trigger assessment of causes and start
intervention
NORMAL
Figure 1. Sarcopenia: EWGSOP2 algorithm for case-finding,making a diagnosis and quantifying severity in practice. Thesteps of the pathway are represented as Find-Assess-Confirm-Severity or F-A-C-S. *Consider other reasons for low musclestrength (e.g. depression, sroke, balance disorders, peripheralvascular disorders).
Sarcopenia: revised European consensus on definition and diagnosis Q1
9
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
Sarcopenic obesity is a distinct condition, and there areongoing initiatives to improve its definition. Sarcopenic obes-ity is therefore outside of the scope of this article.
Frailty
Frailty is a multidimensional geriatric syndrome that is char-acterized by cumulative decline in multiple body systems or
functions [139, 140], with pathogenesis involving physical aswell as social dimensions [141]. Frailty increases vulnerabilityto poor health outcomes such as disability, hospital admis-sion, reduced quality of life and even death [141, 142].
The physical phenotype of frailty, described by Fried andco-workers [143], shows significant overlap with sarcopenia;low grip strength and slow gait speed are characteristic ofboth. Weight loss, another diagnostic criterion for frailty, isalso a major etiologic factor for sarcopenia. Treatmentoptions for physical frailty and for sarcopenia likewise over-lap—provision of optimal protein intake, supplementation ofvitamin D, and physical exercise [19, 144, 145].
Taken together, frailty and sarcopenia are still distinct—one a geriatric syndrome and the other a disease. While sar-copenia is a contributor to the development of physicalfrailty, the syndrome of frailty represents a much broaderconcept. Frailty is seen as the decline over a lifetime in mul-tiple physiological systems, resulting in negative conse-quences to physical, cognitive, and social dimensions.Frailty’s diagnostic tools reflect these multiple dimensions,e.g. the Groningen Frailty Indicator, the Frailty Index ofRockwood et al. and others [146–149].
Malnutrition-associated sarcopenia
The sarcopenia phenotype is also associated with malnutri-tion, regardless of whether the malnourished condition isrooted in low dietary intake (starvation, inability to eat),reduced nutrient bioavailability (e.g. with diarrhea, vomiting)or high nutrient requirements (e.g. with inflammatory dis-eases such as cancer or organ failure with cachexia) [150,151]. Low muscle mass has recently been proposed as partof the definition of malnutrition [152]. Also in malnutrition,low fat mass is usually present, which is not necessarily thecase in sarcopenia [151, 152].
Looking ahead: gaps in sarcopenia research
There are still many gaps in our knowledge about sarcope-nia—its initiation and progression, diagnostic tools and cut-off points, and outcomes.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. EWGSOP sarcopenia cut-off points
Test Cut-off points for men Cut-off points for women References
EWGSOP2 sarcopenia cut-off points for low strength by chair stand and grip strengthGrip strength <27 kg <16 kg Dodds (2014) [26]Chair stand >15 s for five rises Cesari (2009) [67]
EWGSOP sarcopenia cut-off points for low muscle quantityASM <20 kg <15 kg Studenski (2014) [3]ASM/height2 <7.0 kg/m2 <6.0 kg/m2 Gould (2014) [125]
EWGSOP sarcopenia cut-off points for low performanceGait speed ≤0.8 m/s Cruz-Jentoft (2010) [1]
Studenski (2011) [84]SPPB ≤8 point score Pavasini (2016) [90]
Guralnik (1995) [126]TUG ≥20 s Bischoff (2003) [127]400 m walk test Non-completion or ≥6min for completion Newman (2006) [128]
LOW
LOW
POSITIVEOR PRESENT
Sarcopenia suspected
MuscleassessmentMass, Quality
PHYSICAL PERFORMANCE
SPPB, TUG, 400m
Sarcopenia confirmed
LOW Sarcopenia severe
DETERMINE SEVERITY
CONFIRM
FIND CASES
ASSESSMusclestrength
Grip strength, chairstands
NORMAL
rescreenlater
SARC-Forclinical
suspicion
No sarcopenia;rescreen later
Sarcopenia probable*
NEGATIVE
Muscle quantityor quality
DXA; BIA, CT, MRI
PhysicalPerformance
Gait speed, SPPB, TUG, 400m walk
Sarcopenia confirmed
Sarcopenia severeSEVERITY
Muscle strengthGrip strength,
Chair stand test
No sarcopenia; rescreen later
In clinical practice, this is enough to
trigger assessment of causes and start
intervention
NORMAL
Figure 1. Sarcopenia: EWGSOP2 algorithm for case-finding,making a diagnosis and quantifying severity in practice. Thesteps of the pathway are represented as Find-Assess-Confirm-Severity or F-A-C-S. *Consider other reasons for low musclestrength (e.g. depression, sroke, balance disorders, peripheralvascular disorders).
Sarcopenia: revised European consensus on definition and diagnosis Q1
9
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
BGS Autumn 2
018
Early lifeMaximize peak
Age
Mus
cle st
reng
th
Adult lifeMaintain peak
Older lifeMinimize loss
Threshold of disability
Threshold of low physical performance Range of strength in individuals
Time course
Aging
Disease
Inactivity
Malnutrition
• Age-associated muscle loss
• Inflammatory conditions (e.g., organ failure, malignancy)
• Osteoarthritis• Neurological disorders• Sedentary behavior (e.g., limited mobility
or bedrest)• Physical inactivity
• Under-nutrition or malabsorption• Medication-related anorexia• Over-nutrition/obesity
Sarcopenia categories
Acute and chronic sarcopenia
• Acute sarcopenia: less than 6 months.• Usually related to an acute illness or injury.
• Chronic sarcopenia: sarcopenia lasting ≥ 6 months.• Comes with chronic and progressive conditions.
• Underscored the need to conduct periodic sarcopenia assessmentsin individuals at risk.
• May facilitate early intervention.
Some gaps in researchq How can we identify older persons at high risk of sarcopenia?
q Need of normative data to define validated cut-off points
q Management of stature-, gender- and region-dependent measures.
q What muscle quality indicators best predict outcomes?
q What are the kinetics of muscle loss?
q What outcomes are best used as sensitive measures of response to sarcopenia treatments?